FDA Approves AbbVie ’s New Rheumatoid Arthritis Drug

(Reuters)—The U.S. Food and Drug Administration (FDA) on Friday approved AbbVie Inc.’s new treatment for rheumatoid arthritis (RA), a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira (adalimumab)‎‎ faces competition. The drug, Rinvoq (upadacitinib), is a JAK inhibitor. It is set to compete with Pfizer Inc.’s Xeljanz (tofacitinib)... [Read More]

Source: The Rheumatologist - August 19, 2019 Category: Rheumatology Authors: Reuters Staff Tags: DMARDs & Immunosuppressives Drug Updates AbbVie Inc FDA FDA approval Rheumatoid Arthritis (RA) U.S. Food and Drug Administration (FDA) upadacitinib Source Type: research